Session 8 – Combating Pandemics (B)
Date: 23 July (Thursday) 14:00 – 15:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Jane SC Tsai
Jane SC Tsai, PhD, PMP, FAACC, is SVP for International Affairs at YFY Biotech Management Company. She is a Senior Advisor and former Deputy General Director, COO, CTO, and Cross-Institutional Project Leader General at the Biomedical Technology and Device Labs of ITRI in Taiwan. Dr. Tsai has served the roles of a mentor, reviewer, judge, and speaker for several entrepreneurship programs and startup or industrial award competitions. She is a member of the Asian Harmonization Working Party and a former advisor of Clinical and Laboratory Standards Institute. She also provides consultation to biotech and pharma companies and is an Independent Consultant of Guidehouse/Navigant Consulting.
While serving for 16 years as a Research Leader and a Director at Roche Diagnostics, Dr. Tsai directed diverse R&D programs and led various Cross-Functional teams to achieve concept-to-commerce innovations, global product launches, and product lifecycle management. She was a global member in Strategic Visioning, Future-Building, Design Control and Commercialization, Intellectual Properties, Merger-Acquisition Relocations and Integration, and Key Opinion Leader Networking.
Prior to Roche, Dr. Tsai was a Scientist and Principal Investigator in the former Comprehensive Cancer Center of Metropolitan Detroit. She was a research faculty in infectious diseases and host immunity at Penn State University after completing her Ph.D. and Postdoctoral research in Microbiology and Molecular and Cell Biology. She earned her B.S. in Medical Technology from National Taiwan University and worked at the NTU Hospital while pursuing computer programming training. A life-long learner, Dr. Tsai has earned multiple Executive and Professional Certificates in diverse fields, including Project Management, Finance, Clinical Research, Six Sigma Black Belt, Point-of-Care Specialist, and a Graduate Certificate in Healthcare Information Systems.
Speech title & Synopsis
The impact of COVID-19 has upended many aspects of life across the world. The pandemic crisis has rapidly spurred innovations not only in science, technology, and healthcare, but also in regulations and policies. This presentation will provide a succinct overview regarding:
• How have Regulatory Agencies’ Emergency Use Authorization (EUA) or Emergency Market Access for testing and diagnostic products evolved in the context of this public health crisis?
• What are the trends and outlook of Digital Transformations in combating the pandemic?
The magnitude and speed by which a new disease can spread have fueled enormous public and private partnerships, investments, and unprecedented explosions of data and information. Emerging innovations have increasingly been applied to authorized EUA products, including gene-editing, next generation sequencing, and software that uses models derived from machine learning/artificial intelligence, with more new technology developments in the pipeline. This speech will share some take-home questions such as:
• When science goes viral, yet the virus remains quite novel - What’s next?
• How do we harness new and emerging technologies in managing current crises and responding to future threats?